Serotonin, dopamine, and motor effects in Parkinson's disease. 1997

E Miyawaki, and Y Meah, and W C Koller
Department of Neurology, University of Kansas Medical Center, Kansas City 66160-7314, USA.

We review recent reports suggesting that use of selective serotonergic agents that either inhibit synaptic reuptake or have specific serotonin receptor affinities may benefit a variety of motor disturbances in Parkinson's disease. The complex, mixed motoric effects of these agents in Parkinson's disease have not allowed for a consistent view on the interrelationship between dopamine and serotonin (5HT) in motor control but may speak to the nature of dysregulated neurotransmission in the disease.

UI MeSH Term Description Entries
D009069 Movement Disorders Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions. Dyskinesia Syndromes,Etat Marbre,Status Marmoratus,Movement Disorder Syndromes,Dyskinesia Syndrome,Movement Disorder,Movement Disorder Syndrome
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012701 Serotonin A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator. 5-HT,5-Hydroxytryptamine,3-(2-Aminoethyl)-1H-indol-5-ol,Enteramine,Hippophaine,Hydroxytryptamine,5 Hydroxytryptamine
D018490 Serotonin Agents Drugs used for their effects on serotonergic systems. Among these are drugs that affect serotonin receptors, the life cycle of serotonin, and the survival of serotonergic neurons. Serotonergic Agents,Serotonergic Drugs,Serotonin Drugs,Serotonin Effect,Serotonin Effects,Serotoninergic Effect,Serotoninergic Effects,Agents, Serotonergic,Agents, Serotonin,Drugs, Serotonergic,Drugs, Serotonin,Effect, Serotonin,Effect, Serotoninergic,Effects, Serotonin,Effects, Serotoninergic

Related Publications

E Miyawaki, and Y Meah, and W C Koller
June 2019, Cortex; a journal devoted to the study of the nervous system and behavior,
E Miyawaki, and Y Meah, and W C Koller
September 2011, Parkinsonism & related disorders,
E Miyawaki, and Y Meah, and W C Koller
December 2020, Brain : a journal of neurology,
E Miyawaki, and Y Meah, and W C Koller
October 2016, CNS spectrums,
E Miyawaki, and Y Meah, and W C Koller
October 2018, Neuroscience bulletin,
E Miyawaki, and Y Meah, and W C Koller
October 2006, Journal of the neurological sciences,
E Miyawaki, and Y Meah, and W C Koller
November 1981, New York state journal of medicine,
E Miyawaki, and Y Meah, and W C Koller
January 2009, Movement disorders : official journal of the Movement Disorder Society,
E Miyawaki, and Y Meah, and W C Koller
September 1983, Brain research,
E Miyawaki, and Y Meah, and W C Koller
January 2016, Movement disorders : official journal of the Movement Disorder Society,
Copied contents to your clipboard!